Triflusal Triflusal Triflusal is a platelet aggregation inhibitor that was discovered and developed in the Uriach Laboratories, and commercialised in Spain since 1981. Currently, it is available in 25 countries in Europe, Asia, Africa and America. It is a drug of the salicylate family but it is not a derivative of acetylsalicylic acid (ASA). Trade names include Disgren, Grendis, Aflen and Triflux. Triflusal is a selective platelet antiaggregant through; Triflusal is indicated for; In the 2008 guidelines for stroke management from the European Stroke Organization, triflusal was for the first time recommended as lone therapy, as an alternative to acetylsalicylic acid
What Is and What Should Never Be What Is and What Should Never Be "What Is and What Should Never Be" is a song by English rock band Led Zeppelin. It was written by Jimmy Page and Robert Plant and was included as the second track on "Led Zeppelin II" (1969). "What is and What Should Never Be" was one of the first songs on which Page used his soon-to-become trademark Gibson Les Paul for recording. The production makes liberal use of stereo as the guitars pan back and forth between channels. Robert Plant's vocals were phased during the verses. Record producer Rick Rubin has remarked, "The